Dr. Adam Raben, MD

Dr. Raben practices at Radiation Oncologists PA in Newark, Delaware.

Dr. Raben's NPI, 1306888961, was assigned on June 11, 2006. Dr. Raben graduated from Wake Forest University School of Medicine in 1990. Dr. Raben holds Delaware license C10007012.

Dr. Raben's primary practice is Radiation Oncologists PA, at 4701 Ogletown Stanton Rd, Newark, DE 19713 in New Castle County. The practice phone is (302) 733-0806.

Dr. Raben's primary practice is Radiation Oncologists PA in Newark, Delaware. Dr. Raben is also affiliated with Christiana Hospital. The medical group on file is ChristianaCare. Dmand AI also links Dr. Raben to 3 more hospitals, 3 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Raben practices, 7 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Raben's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dmand AI has Dr. Raben's licenses on file in 3 states: Delaware, Maryland and New Jersey.

CMS data shows 4,803 Medicare services from Dr. Raben across 27 procedure codes in 2024, for 387 Medicare patients. Medicare paid $522,426 for them.

CMS counts 387 Medicare patients who saw Dr. Raben in 2024. The largest group is 65 to 74, with 197 patients. 75% of them have cancer, and 75% have high blood pressure. 6% are also on Medicaid. Their average risk score is 1.34, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Raben's median patient age at 70, with 24% women.

In 2024, Dr. Raben wrote 321 Medicare Part D claims for 109 patients. 99% of them were for generic drugs. CMS names the drug for 288 of them, across 9 drugs with 11 or more claims each, at $4,759 in total drug cost. In 2023, CMS named 166 claims across 7 drugs.

Dr. Raben accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 31 papers to Dr. Raben, published from 2013 to 2025. 2015 was the busiest year, with 3. The most frequent topics are Prostatic Neoplasms, Brachytherapy and Radiotherapy Dosage. Dr. Raben has published most often in Int J Radiat Oncol Biol Phys. Dr. Raben's most frequent co-authors are Jeff Michael Michalski, MD, Howard M. Sandler, MD and Elizabeth M. Gore, MD.

Dmand AI links Dr. Raben to 6 clinical trials, 3 of them phase 3 studies. 5 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Pancreatic Intraductal Neoplasms and Prostatic Neoplasms. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 301 general payments to Dr. Raben from 21 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 74% of the total. Bristol-Myers Squibb Company paid the most, $257,095.

Dr. Raben graduated from Wake Forest University School of Medicine in 1990.